---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-130714"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2022-12-29T23:59:59+00:00"
generated_at: "2026-06-20T21:53:56.458177+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics reports FY2022 net loss $66.1M; raises ~$55M; PDUFA date Aug 29, 2023

## Summary
- Net loss $66.1M ($0.31/sh) for FY2022 vs $53.2M ($0.35/sh) in FY2021.
- Cash and equivalents $17.4M at Sept 30, 2022; subsequent financings raised ~$55M gross.
- FDA accepted BLA for ONS-5010; PDUFA goal date set for August 29, 2023.
- Entered strategic commercialization agreement with AmerisourceBergen for 3PL and services.
- Appointed Julia Haller, MD to the Board of Directors.

## SEC filing metadata
- accession: 0001104659-22-130714
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2022-12-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465922130714/0001104659-22-130714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465922130714/tm2233528d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-130714
- JSON: https://secwatch.observer/filing/0001104659-22-130714.json
- Plain text: https://secwatch.observer/filing/0001104659-22-130714.txt

## Key facts
- Earnings Releases
  Outlook Therapeutics, Inc. reported financial results for fiscal year ended September 30, 2022.
  - Period: fiscal year ended September 30, 2022
  - Result: reported results
  source text: On December 29, 2022, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its fourth fiscal quarter and year ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465922130714/0001104659-22-130714-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.